pharma

Advanz Pharma and Alvotech receive European approval for Mynzepli, Biosimilar to Eylea

Mynzepli® (aflibercept) is approved in all European Economic Area member countries for the treatment of various retinal diseases including neovascular…

4 months ago

Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA

ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial…

4 months ago

Caliber Enters 25th Year of Empowering Global Pharma with GxP Digital Solutions

HYDERABAD, India, Aug. 11, 2025 /PRNewswire/ -- Caliber, a leading global provider of GxP-compliant digital solutions for the life sciences…

4 months ago

Zenara Pharma Receives U.S. FDA Approval for First Generic of Sertraline Hydrochloride Capsules with 180-Day CGT Exclusivity

HYDERABAD, India, August 1, 2025 /PRNewswire/ -- Zenara Pharma Private Limited ("Zenara"), a Biophore company, today announced that it has received final…

4 months ago

Dr. Falk Pharma and Allianthera (Suzhou) Biopharmaceuticals Forge Strategic Partnership for Novel AhR Agonist Development

Freiburg (Germany), Suzhou (China) and Boston (USA), July 30, 2025:  Dr. Falk Pharma GmbH and Allianthera (Suzhou) Biopharmaceuticals Co., Ltd.…

4 months ago

Liminatus Pharma, Inc. Initiates Strategic Review of Blockchain-Integrated Treasury Strategy

LA PALMA, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company dedicated to…

5 months ago

HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock

July 18, 2025 16:05 ET  | Source: HOOKIPA Pharma Inc. NEW YORK and VIENNA, July 18, 2025 (GLOBE NEWSWIRE) --…

5 months ago

Vincerx Pharma, Inc. Announces Additional Adjournment of Special Meeting – Urges Stockholders to Vote FOR Approval of Dissolution Proposal

Revised Potential Distribution Range of $0.03 to $0.07 per sharebased on current estimates and assumptions Failure to approve Dissolution Proposal…

5 months ago

Nxera Pharma to Receive US$4.8 Million in Milestone Payments Following Centessas Initiation of Clinical Development of ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist

July 04, 2025 03:00 ET  | Source: Nxera Pharma Tokyo, Japan and Cambridge, UK, 4 July 2025 – Nxera Pharma…

5 months ago

Vincerx Pharma, Inc. Announces Adjournment of Special Meeting – Will Reconvene Meeting on July 16, 2025 to Secure Votes Needed to Approve Dissolution Proposal

SAN MATEO, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (OTC Pink: VINC) today announced that the Special…

6 months ago